RTHP-07. Treatment of Brain Radiation Necrosis With Hyperbaric Oxygen: Report of 6 Cases

Alyahya, Mossaed; Mittal, Sivam; Rowe, David J.; Machtay, Mitch; Ali, Syed Jawwad; Selman, Warren R.; Sloan, Andrew E.; Rogers, Lisa

doi:10.1093/neuonc/nox168.892

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…45 In our cohort, a median of 30 HBOT dives were administered (range 20-60); this is consistent with prior reports, where the number of dives varied between 20 and 60 dives. 12,[14][15][16][17]38,46 Our cohort showed that 92% of the patients improved: 61.5% responded clinically during the course of HBOT, while 30.5% responded within 1 month of HBOT. This is consistent with previous reports that some patients attain clinical response even during a course of HBOT.…”

Section: Treating Necrosismentioning

confidence: 74%

“…In fact, all of the previous studies except one that evaluated HBOT for brain RN found that their patients were on steroids either before or during HBOT (Table 2). 12,[14][15][16][17][18]38,46 Furthermore, the effect of HBOT may be effective against both the reversible and irreversible components of brain RN, but this retrospective study is not able to determine this difference. One of the limitations of the present study was that the steroid use after HBOT was unavailable for review.…”

Section: Treating Necrosismentioning

confidence: 91%

See 1 more Smart Citation

Hyperbaric Oxygen for Radiation Necrosis of the Brain

Moraes

Katznelson

et al. 2019

Can. J. Neurol. Sci.

View full text Add to dashboard Cite

Abstract:Introduction:Hyperbaric oxygen therapy (HBOT) shows promising results in treating radionecrosis (RN) but there is limited evidence for its use in brain RN. The purpose of this study is to report the outcomes of using HBOT for symptomatic brain RN at a single institution.Methods:This was a retrospective review of patients with symptomatic brain RN between 2008 and 2018 and was treated with HBOT. Demographic data, steroid use, clinical response, radiologic response and toxicities were collected. The index time for analysis was the first day of HBOT. The primary endpoint was clinical improvement of a presenting symptom, including steroid dose reduction.Results:Thirteen patients who received HBOT for symptomatic RN were included. The median time from last brain radiation therapy to presenting symptoms of brain RN was 6 months. Twelve patients (92%) had clinical improvement with median time to symptom improvement of 33 days (range 1–109 days). One patient had transient improvement after HBOT but had recurrent symptomatic RN at 12 months. Of the eight patients with evaluable follow-up MRI, four patients had radiological improvement while four had stable necrosis appearance. Two patients had subsequent deterioration in MRI appearances, one each in the background of initial radiologic improvement and stability. Median survival was 15 months with median follow-up of 10 months. Seven patients reported side effects attributable to HBOT (54%), four of which were otologic in origin.Conclusions:HBOT is a safe and effective treatment for brain RN. HBOT showed clinical and radiologic improvement or stability in most patients. Prospective studies to further evaluate the effectiveness and side effects of HBOT are needed.

show abstract